Widespread regional myocardial transfection by plasmid encoding Del-1 following retrograde coronary venous delivery

被引:23
作者
Hou, DM
Maclaughlin, F
Thiesse, M
Panchal, VR
Bekkers, BCAM
Wilson, EA
Rogers, PI
Coleman, MC
March, KL
机构
[1] Indiana Univ, Sch Med, Indianapolis, IN USA
[2] Valentis Inc, Burlingame, CA USA
[3] Richard L Roudebush Vet Adm Med Ctr, Indianapolis, IN 46202 USA
关键词
gene therapy; myocardium; drug administration;
D O I
10.1002/ccd.10417
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study quantifies myocardial transfection following percutaneous retrograde coronary venous delivery (RCVD) of a plasmid encoding human Del-1. RCVD of Del-1, GFP plasmid, or marker dye was conducted in 14 pigs. After selective cannulation of a coronary vein, a delivery site was confirmed by contrast injection and myocardial blush. Ten milliliters of plasmid hDel-1 or GFP was administered. Animals were euthanized 3 and 7 days post-RCVD. hDel-1 gene expression was evaluated by quantitative RT-PCR. An average myocardial expression of 4.5x10(5) copies hDel-1/mug total RNA was observed within the approximately 5 x 5 cm(2) target tissue of the left ventricle. GFP expression was detected by fluorescent microscopy. hDel-1 protein expression was confirmed by immunohistochemistry. Regionalized myocardial expression was found in all pigs. hDel-1 RNA was not found in distant tissues except in the three pigs with prominent venovenous washout (PVW). These levels were 3 to 4 log unites lower than those found in myocardium. Single retrograde coronary venous administration resulted in efficient regional myocyte transfection of hDel-1 and GFP. This method may be useful and clinically feasible for myocardial angiogenesis therapy.
引用
收藏
页码:207 / 211
页数:5
相关论文
共 13 条
[1]  
Boekstegers P, 2001, J Invasive Cardiol, V13, P339
[2]   Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins [J].
Boekstegers, P ;
von Degenfeld, G ;
Giehrl, W ;
Heinrich, D ;
Hullin, R ;
Kupatt, C ;
Steinbeck, G ;
Baretton, G ;
Middeler, G ;
Katus, H ;
Franz, WM .
GENE THERAPY, 2000, 7 (03) :232-240
[3]  
Herity NA, 2000, CATHETER CARDIO INTE, V51, P358, DOI 10.1002/1522-726X(200011)51:3<358::AID-CCD27>3.0.CO
[4]  
2-F
[5]  
HOWELL G, 2000, MOL THER, V1, pS199
[6]   Vector development: a major obstacle in human gene therapy [J].
Jane, SM ;
Cunningham, JM ;
Vanin, EF .
ANNALS OF MEDICINE, 1998, 30 (05) :413-415
[7]   Gene therapy for myocardial angiogenesis [J].
Losordo, DW ;
Vale, PR ;
Isner, JM .
AMERICAN HEART JOURNAL, 1999, 138 (02) :S132-S141
[8]   PHARMACOKINETICS OF ADENOVIRAL VECTOR-MEDIATED GENE DELIVERY TO VASCULAR SMOOTH-MUSCLE CELLS - MODULATION BY POLOXAMER-407 AND IMPLICATIONS FOR CARDIOVASCULAR GENE-THERAPY [J].
MARCH, KL ;
MADISON, JE ;
TRAPNELL, BC .
HUMAN GENE THERAPY, 1995, 6 (01) :41-53
[9]   Investigation of coronary venous anatomy by retrograde venography in patients with malignant ventricular tachycardia [J].
Meisel, E ;
Pfeiffer, D ;
Engelmann, L ;
Tebbenjohanns, J ;
Schubert, B ;
Hahn, S ;
Fleck, E ;
Butter, C .
CIRCULATION, 2001, 104 (04) :442-447
[10]   Del1 induces integrin signaling and angiogenesis by ligation of αVβ3 [J].
Penta, K ;
Varner, JA ;
Liaw, L ;
Hidai, C ;
Schatzman, R ;
Quertermous, T .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (16) :11101-11109